Tempus AI Inc
NASDAQ:TEM
Net Margin
Tempus AI Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
T
|
Tempus AI Inc
NASDAQ:TEM
|
11.2B USD |
-90%
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
10%
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
180.6B USD |
15%
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
147.1B USD |
14%
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
76.1T KRW |
26%
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
39.6B CHF |
10%
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
34.7B USD |
9%
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
34.1B USD |
18%
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
259.8B CNY |
27%
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26.3B USD |
22%
|
|
| IN |
|
Divi's Laboratories Ltd
NSE:DIVISLAB
|
1.8T INR |
24%
|
Tempus AI Inc
Glance View
Tempus AI Inc. stands at the forefront of the healthcare technology revolution, focusing its expertise on the convergence of artificial intelligence and big data to transform the way doctors approach precision medicine. Founded by Eric Lefkofsky in 2015, the company’s mission is to harness the power of data, equipping physicians with crucial insights that can propel patient care forward. With its sprawling genomic database, Tempus aggregates clinical and molecular information, which is then meticulously analyzed to provide actionable insights. Physicians receive comprehensive reports, offering tailored therapeutic options and clinical trial opportunities that might otherwise remain undiscovered. Monetization for Tempus hinges on its relationships with various stakeholders in the healthcare ecosystem. It primarily earns revenue through partnerships with pharmaceutical companies, where it assists in drug discovery and development by offering detailed genomic data and analytics. Moreover, Tempus collaborates with research institutes and healthcare providers who rely on its AI-driven platform to enhance clinical decision-making and improve treatment outcomes. By bridging the gap between vast datasets and intricate patient care solutions, Tempus not only facilitates better healthcare practices but also solidifies its role as a vital link in the evolving landscape of modern medicine.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Tempus AI Inc's most recent financial statements, the company has Net Margin of -89.8%.
You don't have any saved screeners yet